Diagnostic Approach for Ruling Out SLE and Thyroiditis

Laboratory Testing for SLE

The European League Against Rheumatism recommends testing for autoantibodies and complement levels, including ANA, anti-dsDNA, anti-Ro, anti-La, anti-RNP, anti-Sm, anti-phospholipid antibodies, C3, and C4 at baseline 1
Complete blood count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), serum albumin, serum creatinine, urinalysis, and urine protein/creatinine ratio should be performed at 6-12 month intervals in patients with inactive disease, as recommended by the European League Against Rheumatism 1, 2
Re-evaluation of previously negative patients for anti-phospholipid antibodies is recommended prior to pregnancy, surgery, transplant, use of estrogen-containing treatments, or in the presence of new neurological or vascular events, according to the European League Against Rheumatism 1
The European League Against Rheumatism suggests re-evaluating anti-Ro and anti-La antibodies before pregnancy 1
Anti-dsDNA, C3, and C4 may support evidence of disease activity or remission, as stated by the European League Against Rheumatism 1

Disease activity should be evaluated using a validated index at each visit, as recommended by the European League Against Rheumatism 3
Mucocutaneous lesions should be assessed and characterized as LE-specific, LE non-specific, LE mimickers, or drug-related, according to the European League Against Rheumatism 1
Neuropsychological symptoms, including seizures, paresthesiae, numbness, weakness, headache, epilepsy, and depression, should be monitored through focused history, as suggested by the European League Against Rheumatism 3, 4
Cognitive function should be assessed by evaluating attention, concentration, word finding, and memory difficulties, as recommended by the European League Against Rheumatism 3, 4

For patients with persistently abnormal urinalysis or raised serum creatinine, urine protein/creatinine ratio, urine microscopy, and renal ultrasound should be obtained, as recommended by the European League Against Rheumatism 1, 2
Referral for kidney biopsy should be considered in patients with abnormal renal findings, according to the European League Against Rheumatism 1
For established nephropathy, protein/creatinine ratio, immunological tests, urine microscopy, and blood pressure should be monitored at least every 3 months for the first 2-3 years, as suggested by the European League Against Rheumatism 1

The European League Against Rheumatism recommends not relying solely on ANA testing for SLE diagnosis, as it can be positive in other conditions 1

Fatigue, headache, cognitive dysfunction (memory, concentration, word‑finding difficulties), and sleep disturbances are common to both conditions. [5][6]7
Mood disorders, anxiety, depression, and broader neuropsychiatric impairment occur in both fibromyalgia and SLE. [8][9]

Decreased complement C3 and C4 levels are typical during active SLE but remain normal in fibromyalgia. 10
Elevated erythrocyte sedimentation rate (ESR) may be present in SLE, whereas C‑reactive protein (CRP) is usually normal unless infection is present; fibromyalgia shows no inflammatory marker elevation. 10
Hematologic cytopenias (anemia, thrombocytopenia, leukopenia, lymphopenia) are observed in SLE but are absent in fibromyalgia. 10
Abnormal renal laboratory results—including proteinuria, abnormal urinalysis, and elevated serum creatinine—are characteristic of SLE and are not seen in fibromyalgia. 10

Objective organ involvement such as renal disease, serositis, and characteristic cutaneous lesions (malar rash, discoid lesions, photosensitivity) distinguishes SLE from fibromyalgia. [8][10]
Neurological events with objective findings—seizures, cerebrovascular disease, and peripheral neuropathy—are associated with SLE. [8][9]

Widespread musculoskeletal pain with >11 of 18 tender points, together with a lowered pain threshold manifested as hyperalgesia and allodynia, is a hallmark of fibromyalgia. [5][6]
Gastro‑intestinal and genitourinary symptoms such as variable bowel habits, diffuse abdominal pain, and increased urinary frequency are more strongly linked to fibromyalgia than to SLE. [5][6]

The presence of objective organ involvement (renal, hematologic, or cutaneous) should be sought; its absence argues against a diagnosis of SLE. 10
Validated disease‑activity indices for SLE (e.g., SLEDAI, BILAG) should be employed at each visit to separate true lupus activity from fibromyalgia‑related symptoms. 9